Your session is about to expire
← Back to Search
Intensity Modulated Total Marrow Irradiation + Fludarabine Phosphate + Melphalan for Hematologic Cancers
Study Summary
This trial is testing IMTMI to see if it's less toxic and more effective than other types of radiation therapy when given with fludarabine and melphalan to patients with relapsed blood cancer before a stem cell transplant.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have AML or high-risk MDS and am undergoing a second stem cell transplant for relapse, or I have another blood cancer as decided by my doctors.I am able to care for myself but cannot carry on normal activity or do active work.My heart and lungs are working well enough for the trial.I do not have chronic hepatitis or cirrhosis.My donor for the second stem cell transplant is the same or another matched donor.
- Group 1: Treatment (IMTMI, combination chemotherapy, PBSCT or BMT)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any short- or long-term risks associated with Allogeneic Hematopoietic Stem Cell Transplantation?
"Due to the limited safety and efficacy data present, our team at Power has assigned Allogeneic Hematopoietic Stem Cell Transplantation a rating of 1."
What is the enrollment size of this clinical trial?
"Affirmative, information posted on clinicaltrials.gov states that this medical trial is actively sourcing participants. Initially launching on December 5th 2014 and updated as recently at January 7th 2022, the study seeks to recruit 30 patients from a single site."
What are the criteria for joining this research study?
"In order to be eligible for this trial, participants must have acute myelocytic leukemia and lie within the age range of 18-75. The study is seeking roughly 30 individuals."
What medical conditions benefit from Allogeneic Hematopoietic Stem Cell Transplantation?
"Allogeneic Hematopoietic Stem Cell Transplantation is frequently used to treat dermatitis, atopic. It may also be beneficial in the management of rejection; transplant, liver, rejection; transplant, kidney and psoriasis ailments."
Are there any enrollment opportunities at present for this research project?
"Data from clinicaltrials.gov attests that this trial is actively seeking new participants, with the initial posting on December 5th 2014 and its most recent update being January 7th 2022."
Does this research encompass geriatric patients?
"To qualify for this experiment, potential participants must be between 18 and 75 years old. Additionally, there are 1078 trials available to those under 18 years of age and 4728 options exist for patients over 65."
Could you please provide an overview of other experiments involving Allogeneic Hematopoietic Stem Cell Transplantation?
"Currently, there are 574 trials ongoing for Allogeneic Hematopoietic Stem Cell Transplantation. Out of these studies, 62 have progressed to Stage 3. Philadelphia is the epicentre of research in this field; however, it can be accessed at 6491 sites across the world."
Share this study with friends
Copy Link
Messenger